<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471808</url>
  </required_header>
  <id_info>
    <org_study_id>13560475186</org_study_id>
    <nct_id>NCT01471808</nct_id>
  </id_info>
  <brief_title>Effects of Different Early Intensive Therapies on Long-term β-cell Function</brief_title>
  <official_title>Effects of Oral Hypoglycemic Agents Combined With Short-term CSII on Glycemic Control in Newly-diagnosed Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and evaluate the effects of different oral
      antihyperglycaemic agents combined with short-term continuous subcutaneous insulin
      infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone combined with CSII; 3. sitagliptin
      combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type
      2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control after short intensive therapy in newly diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the improvement of β-cell function after short intensive therapy in newly diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effects of different interventions on glycemic control in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effects of different interventions on β-cell function in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effects of different interventions on the remission rate in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuous subcutaneous insulin infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin &amp; Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII combined with metformin and pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII combined with sitagliptin 100mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII</intervention_name>
    <description>continuous subcutaneous insulin infusion for 2~4 weeks</description>
    <arm_group_label>CSII</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII, Metformin, Pioglitazone</intervention_name>
    <description>CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.</description>
    <arm_group_label>Metformin &amp; Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII, Sitagliptin</intervention_name>
    <description>CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed type 2 diabetes

          -  fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L

          -  body mass index (BMI) ranging from20～35kg/m2

          -  Antihyperglycaemic and antihyperlipidemic medication-naive patients

        Exclusion Criteria:

          -  having any severe acute or chronic diabetic complications

          -  renal dysfunction, blood creatinine≥150µmol/L

          -  blood aminotransferase level rising up(more than 2 times of the upper normal limit of
             ALT)

          -  • Any severe cardiac disease including congestive cardiac failure, unstable angina or
             myocardial infarct in 12 months

          -  chronic or acute pancreatic disease

          -  severe systematic diseases or malignant tumor

          -  female patients incline to be pregnant

          -  being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs

          -  poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanbin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Education</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanbing Li</investigator_full_name>
    <investigator_title>the director of the endocrinology department of the First Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

